News
GNPX
1.175
+10.85%
0.115
Weekly Report: what happened at GNPX last week (1202-1206)?
Weekly Report · 4d ago
Weekly Report: what happened at GNPX last week (1125-1129)?
Weekly Report · 12/02 11:58
Weekly Report: what happened at GNPX last week (1118-1122)?
Weekly Report · 11/25 11:48
Genprex signs exclusive license agreement with University of Michigan
TipRanks · 11/20 14:37
GENPREX INC - RECEIVES NASDAQ NOTICE FOR NON-COMPLIANCE WITH EQUITY REQUIREMENT
Reuters · 11/19 22:17
Weekly Report: what happened at GNPX last week (1111-1115)?
Weekly Report · 11/18 11:44
Based on the provided financial report article, the title of the article is likely: "Genprex, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2024" This title is inferred from the information provided, which includes the company name, the reporting period, and the type of financial report (10-Q).
Press release · 11/13 21:52
Weekly Report: what happened at GNPX last week (1104-1108)?
Weekly Report · 11/11 12:01
Genprex to present positive preclinical data from Reqorsa Gene Therapy study
TipRanks · 11/05 14:35
GENPREX INC: REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
Reuters · 11/05 14:31
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
Benzinga · 11/04 16:05
Weekly Report: what happened at GNPX last week (1028-1101)?
Weekly Report · 11/04 11:57
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 10/28 20:30
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 10/28 16:30
Looking Into Genprex's Recent Short Interest
Benzinga · 10/28 15:30
Weekly Report: what happened at GNPX last week (1021-1025)?
Weekly Report · 10/28 11:47
Biotech Alert: Searches spiking for these stocks today
TipRanks · 10/25 14:45
Genprex signs two lung cancer research agreements
TipRanks · 10/24 13:35
Genprex Announces Sponsored Research Agreement With The University Of Michigan Rogel Cancer Center To Study TUSC2, The Tumor Suppressor Gene Used In Genprex's Lead Drug Candidate, Reqorsa Gene Therapy, In Combination With ALK-Inhibitors In ALK-EML4 Positive Translocated Lung Cancer
Benzinga · 10/24 13:32
More
Webull provides a variety of real-time GNPX stock news. You can receive the latest news about Genprex Inc through multiple platforms. This information may help you make smarter investment decisions.
About GNPX
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles. The Company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Using a different gene therapy delivery system, the Company is also developing its preclinical diabetes candidate GPX-002 using the same construct for both Type 1 diabetes and Type 2 diabetes. It conducts preclinical research to explore how REQORSA may be administered in other solid tumors.